Comparison of Continuous Blood Glucose Measurement with Conventional Documentation of Hypoglycemia in Patients with Type 2 Diabetes on Multiple Daily Insulin Injection Therapy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The primary objective of this study was to investigate the difference in the proportion of patients with conventionally detected hypoglycemia compared with continuous glucose monitoring system (CGMS, Medtronic MiniMed, Sylmar, CA)-detected glucose values < or = 60 mg/dL (< or = 3.3 mmol/L), during the 72-h CGMS measurement period after 8 weeks' treatment with insulin glargine. METHODS: This was a multicenter (n = 125), open-label, single-arm study in patients with Type 2 diabetes mellitus (T2DM) on multiple daily injections. Patients received NPH insulin (2-week run-in) followed by glargine (8-week treatment phase). Glucose levels were measured by CGMS and self-monitored blood glucose (SMBG) profiles over the 72-h pre- and post-treatment phase. RESULTS: The full analysis set contained 367 patients [male 59%; mean age 59.2 years; mean body mass index 31.7 kg/m(2); mean hemoglobin A1c (HbA1c) 6.9%]. At end point, 209 patients (56.9%) experienced hypoglycemia according to CGMS; 97 (26.4%) recorded hypoglycemia by conventional methods. CGMS- and SMBG-determined mean daytime glucose levels were similar at baseline and end point; however, nocturnal glucose levels were significantly lower with CGMS versus SMBG at baseline [130.2 vs. 145.0 mg/dL (7.2 vs. 8.1 mmol/L)] and at end point [123.3 vs. 137.3 mg/dL (6.8 vs. 7.6 mmol/L)]. Glucose levels measured by CGMS and SMBG decreased, and HbA1c levels decreased from 6.90% at screening to 6.67% at end point (P < 0.001). CONCLUSIONS: This study demonstrates that CGMS can be successfully employed in large clinical trial settings in patients with T2DM. This easy-to-implement method may provide additional insights into glucose levels and valuable information regarding the time patients spend within the preferred glucose range.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Cryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160 · cited 1×
“4 Though the frequency of overall episodes of hypoglycemia is lower in patients with T2DM versus Type 1 diabetes (T1DM), 5,6 studies indicate that rates of hypoglycemia are associated with duration rather than type of disease.”
Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 1×
“4 Though the frequency of overall episodes of hypoglycemia is lower in patients with T2DM versus Type 1 diabetes (T1DM), 5,6 studies indicate that rates of hypoglycemia are associated with duration rather than type of disease.”
Diverse causes of hypoglycemia-associated autonomic failure in diabetes.
Cryer, P. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmra031354 · Cited by 411 · cited 1×
“7 Indeed, the incidence of severe hypoglycemia has been re-ported to be similar in patients with T2DM and T1DM if patients are matched for the duration of insulin therapy.”
Chico, A., Vidal-Ríos, P., Subirà, M., & Novials, A. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1153 · Cited by 235
Cited by
Vigersky, R. A., Fonda, S. J., Chellappa, M., Walker, M. S., & Ehrhardt, N. M. (2012) · Diabetes Care · doi:10.2337/dc11-1438 · Cited by 301
Silbert, R., Salcido-Montenegro, A., Rodriguez-Gutierrez, R., Katabi, A., & McCoy, R. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1018-0 · Cited by 229
Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline
Klonoff, D. C., Buckingham, B., Christiansen, J. S., Montori, V. M., Tamborlane, W. V., Vigersky, R. A., & Wolpert, H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2756 · Cited by 211
Ehrhardt, N. M., Chellappa, M., Walker, M. S., Fonda, S. J., & Vigersky, R. A. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500320 · Cited by 199
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0255-6 · Cited by 188
Janapala, R. N., Jayaraj, J. S., Fathima, N., Kashif, T., Usman, N., Dasari, A., Jahan, N., & Sachmechi, I. (2019) · Cureus · doi:10.7759/cureus.5634 · Cited by 117
“Studies demonstrated that CGMs detected a significantly higher number of hypoglycemic events than the SMBG or symptomatic hypoglycemia [20-23].”
BackgroundType 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring
Jackson, M. A., Ahmann, A., & Shah, V. N. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0007 · Cited by 106
Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts
Abraham, S. B., Arunachalam, S., Zhong, A., Agrawal, P., Cohen, O., & McMahon, C. M. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819859334 · Cited by 63
Evolution of Devices in Diabetes Management
Penfornis, A., Personeni, E., & Borot, S. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0058 · Cited by 49
“The advent of CGM offers the opportunity to increase the duration of time spent within glycemic thresholds for adults and children, 53–55 thereby improving overall diabetes management.”
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
Hypoglycaemia and its management in primary care setting
Ibrahim, M., Baker, J., Cahn, A., Eckel, R. H., El Sayed, N. A., Fischl, A. H., Gaede, P., Leslie, R. D., Pieralice, S., Tuccinardi, D., et al. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3332 · Cited by 21
“The frequency of CGM detected hypoglycaemia events can reach several-fold higher than that of self-reported hypoglycaemia by BGM in insulin-treated patients.76 Even in T2DM patients, a short period of CGM use (72 hours), there was a 2-fold increase in the detection of hypoglycaemia events as compared to SMBG.77 In T1D…”
Influential
Metadata
- Authors
- Zick, R., Petersen, B., Richter, M., Haug, C., & on Behalf of the SAFIR Study Group
- Venue
- Diabetes Technology & Therapeutics
- Publisher
- SAGE Publications
- Published
- 2007-12
- Volume
- 9
- Issue
- 6
- Pages
- 483-492
- ISSN
- 1520-9156 (ISSN-L)
- 1557-8593
- OpenAlex
- W2003739018
- Cited by
- 64
- References
- 5
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.